WallStSmart

Abbott Laboratories (ABT)vsHyperfine Inc (HYPR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 294335% more annual revenue ($45.13B vs $15.33M). ABT leads profitability with a 13.9% profit margin vs -226.9%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

HYPR

Avoid

23

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -7.66
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-24.7%)

Margin of Safety

-24.7%

Fair Value

$70.91

Current Price

$90.50

$19.59 premium

UndervaluedFair: $70.91Overvalued

Intrinsic value data unavailable for HYPR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$154.45B9/10

Large-cap with strong market position

HYPR1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
82.6%10/10

Revenue surging 82.6% year-over-year

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

HYPR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$158.83M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-101.2%2/10

ROE of -101.2% — below average capital efficiency

Free Cash FlowQuality
$-9.25M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bull Case : HYPR

The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 82.6% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : HYPR

The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while HYPR is a hypergrowth play — different risk/reward profiles.

HYPR carries more volatility with a beta of 1.42 — expect wider price swings.

HYPR is growing revenue faster at 82.6% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Hyperfine Inc

HEALTHCARE · MEDICAL DEVICES · USA

Hyperfine Inc. is a leading medical technology innovator that has revolutionized imaging diagnostics with the introduction of the first FDA-cleared portable MRI system. This groundbreaking solution enhances accessibility to imaging directly at the point of care, thereby improving patient outcomes and expediting clinical decision-making. By prioritizing cost efficiency and convenience, Hyperfine is well-positioned to capitalize on burgeoning market opportunities, making it an appealing investment for institutional investors interested in transformative healthcare advancements.

Visit Website →

Want to dig deeper into these stocks?